What happened in Q3? Did the glimmers of light we saw at the start of the quarter really come to anything or were they a false dawn? In this eBook, we investigate whether a year that started out looking pretty grim is actually staging a turnaround that a beleaguered industry would welcome. 

Were small biotechs finally accepting the inevitable and taking deals that they’d have laughed at a year ago? And are the big pharma players starting to work on plugging the pipeline ahead of the impending patent cliff? Download your copy now to find out. 



The biopharma flotation remains a rare beast

No big bang for biopharma buyouts
Venture investors keep the purse strings tight
The gloom deepens for biopharma stocks
Few safe havens surface for biopharma